Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial

Abstract

The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et al. in J Clin Oncol 33:594–601, 2015). Eligible patients received eribulin (1.4 mg/m2 intravenously on days 1 and 8) or capecitabine (1.25 g/m2 orally twice daily on days 1–14) per 21-day cycles. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 questions (QLQ-C30) and breast module-23 questions (QLQ-BR23), administered at baseline through 24 months, until disease progression or other antitumor treatment initiation. Minimally important difference (MID) and time to symptom worsening (TSW) were investigated. 1062 (96.4 %) Patients completed the EORTC questionnaire at baseline; overall, compliance was ≥80 %. Patients receiving capecitabine versus eribulin had significantly worse symptoms (higher scores) for nausea/vomiting (MID 8; P < 0.05) and diarrhea (MID 7; P < 0.05). Treatment with eribulin versus capecitabine, led to worse systemic therapy side-effects (dry mouth, different tastes, irritated eyes, feeling ill, hot flushes, headaches, and hair loss; MID 10; P < 0.01). Clinically meaningful worsening was observed for future perspective (MID 10; P < 0.05) with capecitabine and for systemic therapy side-effects scale (MID 10; P < 0.01) with eribulin. Patients receiving capecitabine experienced more-rapid deterioration in body image (by 2.9 months) and future perspective (by 1.4 months; P < 0.05) compared with those on eribulin; the opposite was observed for systemic side-effects where patients receiving eribulin experienced more-rapid deterioration than those receiving capecitabine (by 2 months; P < 0.05). Eribulin and capecitabine were found to have similar impact on patient functioning with no overall difference in HRQoL. Patients receiving eribulin reported worse systemic side-effects of chemotherapy but reduced gastrointestinal toxicity compared with capecitabine.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-015-3633-7) contains supplementary material, which is available to authorized users.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE

“…Baseline HRQL parameters of physical functioning, pain, and appetite loss provided significant prognostic information, in addition to the parameters of age, sex, and distant metastases , and recent clinical trials of newer agents, including eribulin, incorporated quality‐of‐life analyses among prespecified clinical endpoints . To preserve quality of life in the case of an incurable disease such as MBC, beneficial therapies should reduce tumor burden and tumor‐related symptoms and have an easily manageable toxicity profile .…”

“…To preserve quality of life in the case of an incurable disease such as MBC, beneficial therapies should reduce tumor burden and tumor‐related symptoms and have an easily manageable toxicity profile . When eribulin or capecitabine were administered in patients with locally advanced MBC or with MBC previously treated with an anthracycline and taxane, they maintained or improved patients' functioning and quality of life and showed favorable safety results compared with baseline . However, significant differences were described in the timing and type of side effects, mirroring a peculiar toxicity profile for each drug: Patients treated with capecitabine had worse scores, and more rapid time to symptom worsening for gastrointestinal symptoms, whereas patients treated with eribulin had worse scores for systemic therapy side effects; all differences were greatest at 6 weeks, and tended to decline thereafter .…”

The Position of Combination Chemotherapy with Mitomycin C and Methotrexate in the Treatment of Metastatic Breast Cancer - Especially Triple Negative Breast Cancer

“…For example, platinum analogues such as carboplatin and cisplatin, which act directly and cross-link DNA, are effective treatments for TN-breast cancer, especially in patients with germline mutations of BRCA1/2 [8]. Capecitabine and eribulin are treatment choices for TN-MBC, based on clinical effectiveness having been reported in several subgroup analyses [9][10][11]. Recently, synergistic antitumor effects of S-1 with eribulin in vitro as well as in vivo for TN-breast cancer cell lines have been reported [12].…”

The Potential Protective Role of Hesperidin Against Capecitabine-Induced Corneal Toxicity in Adult Male Albino Rat. Light and Electron Microscopic Study

“…The improved tolerability and efficacy of capecitabine compared with intravenous 5-FU, in addition to its oral route of administration make it the best choice for different classes of carcinomas as colorectal, breast and pancreatic carcinomas [9][10][11] . Diarrhea, hand-foot syndrome and oromandibular dystonia are frequent complications for capecitabine treatment [12][13][14] . Moreover, ocular complications such as ocular irritation, decreased vision and corneal deposits have been associated with capecitabine therapy [15] .…”